1111 related articles for article (PubMed ID: 28368458)
1. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Chaput N; Lepage P; Coutzac C; Soularue E; Le Roux K; Monot C; Boselli L; Routier E; Cassard L; Collins M; Vaysse T; Marthey L; Eggermont A; Asvatourian V; Lanoy E; Mateus C; Robert C; Carbonnel F
Ann Oncol; 2017 Jun; 28(6):1368-1379. PubMed ID: 28368458
[TBL] [Abstract][Full Text] [Related]
2. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP; Fontana V; Morabito A; Dozin B; Laurent S; Carosio R; Banelli B; Ferrero F; Spano L; Tanda E; Ferrucci PF; Martinoli C; Cocorocchio E; Guida M; Tommasi S; De Galitiis F; Pagani E; Antonini Cappellini GC; Marchetti P; Quaglino P; Fava P; Osella-Abate S; Ascierto PA; Capone M; Simeone E; Romani M; Spagnolo F; Queirolo P;
Cancer Immunol Immunother; 2019 Jan; 68(1):97-107. PubMed ID: 30311027
[TBL] [Abstract][Full Text] [Related]
3. Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma.
Ladányi A; Papp E; Mohos A; Balatoni T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Ferrone S
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554608
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
Lesage C; Longvert C; Prey S; Maanaoui S; Dréno B; Machet L; Zehou O; Kramkimel N; Jeudy G; Skowron F; Aubin F; Visseaux L; Mansard S; Dereure O; Lesage FX; Guillot B;
J Immunother; 2019 Jun; 42(5):175-179. PubMed ID: 31090656
[TBL] [Abstract][Full Text] [Related]
5. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
Usyk M; Pandey A; Hayes RB; Moran U; Pavlick A; Osman I; Weber JS; Ahn J
Genome Med; 2021 Oct; 13(1):160. PubMed ID: 34641962
[TBL] [Abstract][Full Text] [Related]
6. Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events.
Desilets A; Elkrief A
Curr Opin Oncol; 2023 Jul; 35(4):248-253. PubMed ID: 37222188
[TBL] [Abstract][Full Text] [Related]
7. Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade.
Gao Y; Xu P; Sun D; Jiang Y; Lin XL; Han T; Yu J; Sheng C; Chen H; Hong J; Chen Y; Xiao XY; Fang JY
Cancer Res; 2023 Nov; 83(22):3710-3725. PubMed ID: 37602831
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study.
Franzen D; Schad K; Kowalski B; Clarenbach CF; Stupp R; Dummer R; Kohler M
Cancer Immunol Immunother; 2018 Jan; 67(1):127-134. PubMed ID: 28983773
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer.
Chang JW; Hsieh JJ; Tsai CY; Chiu HY; Lin YF; Wu CE; Shen YC; Hou MM; Chang CY; Chen JA; Chen CL; Chiu CT; Yeh YM; Chiu CH
Biomed J; 2024 Jan; ():100698. PubMed ID: 38280521
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Baseline Tumor Burden with Clinical Outcome in Melanoma Patients Treated with Ipilimumab.
Angelova-Toshkina D; Weide B; Tietze LF; Hebst M; Tietze JK
Oncology; 2024; 102(1):76-84. PubMed ID: 37579734
[TBL] [Abstract][Full Text] [Related]
11. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab.
Bjoern J; Juul Nitschke N; Zeeberg Iversen T; Schmidt H; Fode K; Svane IM
Oncoimmunology; 2016 Apr; 5(4):e1100788. PubMed ID: 27141381
[No Abstract] [Full Text] [Related]
12. Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.
Kverneland AH; Enevold C; Donia M; Bastholt L; Svane IM; Nielsen CH
Oncoimmunology; 2018; 7(5):e1424674. PubMed ID: 29721387
[No Abstract] [Full Text] [Related]
13. Checkpoint inhibitor responses can be regulated by the gut microbiota - A systematic review.
Zeriouh M; Raskov H; Kvich L; Gögenur I; Bennedsen ALB
Neoplasia; 2023 Sep; 43():100923. PubMed ID: 37603952
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis.
Arriola E; Wheater M; Lopez MA; Thomas G; Ottensmeier C
Oncoimmunology; 2016; 5(9):e1209615. PubMed ID: 27757302
[TBL] [Abstract][Full Text] [Related]
15. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.
Damuzzo V; Solito S; Pinton L; Carrozzo E; Valpione S; Pigozzo J; Arboretti Giancristofaro R; Chiarion-Sileni V; Mandruzzato S
Oncoimmunology; 2016; 5(12):e1249559. PubMed ID: 28123888
[TBL] [Abstract][Full Text] [Related]
16. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.
Alves Costa Silva C; Piccinno G; Suissa D; Bourgin M; Schreibelt G; Durand S; Birebent R; Fidelle M; Sow C; Aprahamian F; Manghi P; Punčochář M; Asnicar F; Pinto F; Armanini F; Terrisse S; Routy B; Drubay D; Eggermont AMM; Kroemer G; Segata N; Zitvogel L; Derosa L; Bol KF; de Vries IJM
Nat Commun; 2024 Feb; 15(1):1633. PubMed ID: 38395948
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibitor-Induced Colitis.
Thomas AS; Wang Y
Am J Gastroenterol; 2020 Aug; 115(8):1301-1302. PubMed ID: 32756260
[No Abstract] [Full Text] [Related]
18. Expression of Concern: Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells.
PLOS ONE Editors
PLoS One; 2023; 18(1):e0280115. PubMed ID: 36630385
[No Abstract] [Full Text] [Related]
19. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
